<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577119</url>
  </required_header>
  <id_info>
    <org_study_id>18-0295</org_study_id>
    <nct_id>NCT03577119</nct_id>
  </id_info>
  <brief_title>Full-fat Yogurt and Glucose Tolerance</brief_title>
  <official_title>Full-fat Yogurt and Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Dairy Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines if substituting full-fat yogurt (i.e., whole, 3.25% fat) for non-fat
      yogurt in the diet can reduce the risk of type 2 diabetes and inflammation in association
      with changes in the composition of the gastrointestinal bacteria prediabetic male and female
      volunteers. The central hypothesis is that dairy fat impacts whole body glucose handling and
      insulin sensitivity as well as inflammation both directly, and indirectly via influencing the
      gut microbiota composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this study is to determine if substituting full-fat yogurt (i.e.,
      whole, 3.25% fat) for non-fat yogurt in the diet can i) improve whole body glucose handling
      and insulin sensitivity, ii) modulate systemic inflammation, and iii) induce putatively
      beneficial changes in the composition of the colonic microbiota in prediabetic men and women.
      By comparing a diet containing non-fat yogurt with a diet comprising of full-fat yogurt, the
      investigators will address the following specific hypotheses and aims:

      Hypothesis 1: Dietary intake of full-fat yogurt will improve fasting and postprandial markers
      of glucose homeostasis, insulin sensitivity, and pancreatic cell function. Aim 1: Evaluating
      the diet-induced changes in blood glucose and endogenous insulin secretion. This will be
      assessed through a mixed meal tolerance test and oral glucose tolerance test.

      Hypothesis 2: Dietary intake of full-fat yogurt will relatively reduce systemic inflammation.
      Aim 2: Examine diet-induced changes in inflammatory tone. This will be assessed through
      measurements of circulating (plasma) pro- and anti-inflammatory cytokines, cytokine
      production assays from in vitro-stimulated peripheral blood mononuclear cells, and plasma
      stimulated cytokine production in immortalized human cell lines.

      Hypothesis 3: A diet containing full-fat yogurt will alter the colonic bacteria structure
      (e.g. decrease the Firmicutes/Bacteroidetes ratio). Aim 3: Characterize diet-induced
      alterations in colonic bacteria structure (composition and density) via next-generation
      sequencing and real-time Polymerase Chain Reaction Assays (PCR).

      This study recruits 32 pre-diabetic female and male volunteers (50:50) aged 45-75 using a
      double-blinded, randomized crossover design to compare two experimental diets, 1) a low-fat
      diet containing fat-free yogurt (total fat: 28% energy), and 2) a higher fat diet consisting
      of whole 3.25% fat yogurt (total fat: 38% energy). Fat in the whole yogurt accounts entirely
      for the arithmetic difference in fat of 10% energy between the two diets. The study will
      consist of two 21-day experimental diet periods preceded by a 7-day control diet. The total
      length of study will be 8 weeks. The diet during the control diet periods will be an average
      U.S. diet to establish a normalized fatty acid intake among the subjects and to standardize
      the subject's physiologic state before each experimental diet. At the end of the first
      control period (&quot;run-in&quot;) and at the end of each of the experimental diets, a mixed meal
      tolerance test and an oral glucose test will be performed to assess diet-induced changes in
      whole-body glucose handling and insulin sensitivity. In addition, blood and stool samples
      will be collected to examine diet-induced alterations in inflammatory tone and
      gastrointestinal microflora.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Accrual on hold due to temporary pandemic research policy.
  </why_stopped>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study will employ a controlled, randomized, double-blinded crossover trial comparing two diets.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in insulin sensitivity and β-cell function: MMTT</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluated through mixed meal tolerance test (MMTT) prior to and post experimental diets. Tests will be quantified using the area under the curve (AUC) of the temporal changes in blood glucose, insulin, C-peptide, and incretins (GLP-1 and GIP) using fasting and serial postprandial blood samples. All measurements will be reported as mol/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in insulin sensitivity and β-cell function: OGTT</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluated through oral glucose tolerance test (OGTT) prior to and post experimental diets. Tests will be quantified using the area under the curve (AUC) of the temporal changes in blood glucose, insulin, C-peptide, and incretins (GLP-1 and GIP) using fasting and serial postprandial blood samples. All measurements will be reported as mol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluated through measurements of circulating (plasma) pro- and anti-inflammatory cytokines, cytokine production assays from in vitro-stimulated peripheral blood mononuclear cells, and plasma stimulated cytokine production in immortalized human cell lines prior to and post experimental diets. Inflammatory markers that will be measured are: interleukins 1beta, 6, 8, and 10 (IL-1beta, IL-6, IL-8, and IL-10), and tumor necrosis factor alpha (TNFalpha). All measurements will be reported as pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to Colonic microbiota structure: density</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluated through analysis of colonic bacteria structure (composition and density) of specific colonic microbiota prior to and post experimental diets. Density of colonic bacteria will be measured in log copies/ug feces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to Colonic microbiota structure: relative abundance</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluated through analysis of colonic bacteria structure (composition and density) of specific colonic microbiota prior to and post experimental diets. Relative abundance of Taxa of colonic bacteria will be reported as a percentage (%).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Pre-Diabetes</condition>
  <arm_group>
    <arm_group_label>Full-fat yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-fat yogurt (Control)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Full-fat yogurt</intervention_name>
    <description>Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.</description>
    <arm_group_label>Full-fat yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Non-fat yogurt</intervention_name>
    <description>Controlled diet that includes three daily servings of fat-free yogurt.</description>
    <arm_group_label>Non-fat yogurt (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women and not expecting major lifestyle changes while on study

          -  Age 45-75

          -  Overweight and obesity (BMI 20-45 kg/m2)

          -  Stable body weight for the last 6 months (no more than a +/- 5% change)

          -  Diagnosis of prediabetes, defined as either impaired fasting glucose (fasting glucose:
             100-125 mg/dL), impaired glucose tolerance (blood glucose levels of between: 140-199
             mg/dL 2-hr post 75-g oral glucose tolerance test), and/or a hemoglobin A1C (HbA1C)
             level ranging from 5.7% to 7.0% (if HbA1C above 6.4%, monotherapy of Metformin)

          -  Women: Post-Menopausal: no menses previous 12 mos.; Follicular Stimulating Hormone
             (FSH) &gt; 20 mIU/mL

          -  Consuming at least 25% of calories from fat (screening will be based an online fat
             screener:

        http://nutritionquest.com/wellness/free-assessment-tools-for-individuals/fat-intake-screene
        r/

          -  Normal cognition

          -  Read and understand English

          -  Have a telephone

          -  Willing to follow the study coordinator's/manager's and dietitian's instructions

        Exclusion Criteria:

          -  Fasting blood glucose ≥126 mg/dL, HbA1C ≥7.0% without monotheraoy of Metformin

          -  Subject with any chronic disease, inflammatory disease (e.g., asthma, rheumatoid
             arthritis, Crohn's disease or inflammatory bowel disease) and previous diagnosis of
             HIV or hepatitis C

          -  Pregnant or breastfeeding women or women on hormone replacement therapy (for previous
             3 months)

          -  Intolerance to dairy foods (i.e., lactose intolerance or protein allergy), food
             allergies, or significant food preferences, dietary restrictions (vegetarian, vegan
             lifestyle), or food aversions that would interfere with diet adherence

          -  History of a diagnosed eating disorder

          -  Known/diagnosed gastrointestinal problems (e.g., inflammatory bowel disease, irritable
             bowel syndrome, etc.)

          -  Antibiotics use during the past 6 months

          -  Habitual use of tobacco or controlled substances, and dietary supplements during the
             study and 1 month prior to the study

          -  On medically prescribed diets or following a diet (e.g., to lose weight) or use of
             obesity or weight-loss treatments such as dietary interventions or pharmacotherapy

          -  Chronic anti-inflammatory medications, or frequent use (&gt;25% of the time) of
             over-the-counter medication including laxatives and antacids (subjects with occasional
             use of allergy or cold medicine, NSAIDS, acetaminophen, or aspirin will be recruited,
             but these drugs will not be permitted during the study, except for acute
             administration up to 3 days prior to the outcome variables).

          -  Waist circumference &gt;40 inches in men and &gt;35 inches in women

          -  Current diagnosis of uncontrolled hypertension (systolic BP: &gt;160mmHg, diastolic BP:
             &gt;95mmHg), (may receive treatment for hypertension as long as 1) on a stable regime for
             the previous 6 wk, and 2) no anticipated change while on the study)

          -  Untreated hyperlipidemia [may receive treatment for hyperlipidemia (statins) as long
             as 1) on a stable regime for the previous 6 wk, and 2) no anticipated change while on
             the study)

          -  Participation on regular basis in competitive sports or habitual aerobic exercise
             training, which we will arbitrarily define a consisting of &gt; 3 bouts/wk of aerobic
             exercise (unable to speak comfortably) for more than 20 min

          -  Lifestyle or schedule incompatible with the study protocol

          -  Psychiatric or behavioral conditions that in the view of the principal investigator
             may present a safety hazard to the participant or interfere with study participation
             or the ability to follow the intervention protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana Kraft, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Holmberg S, Thelin A. High dairy fat intake related to less central obesity: a male cohort study with 12 years' follow-up. Scand J Prim Health Care. 2013 Jun;31(2):89-94. doi: 10.3109/02813432.2012.757070. Epub 2013 Jan 15.</citation>
    <PMID>23320900</PMID>
  </reference>
  <reference>
    <citation>Kratz M, Baars T, Guyenet S. The relationship between high-fat dairy consumption and obesity, cardiovascular, and metabolic disease. Eur J Nutr. 2013 Feb;52(1):1-24. doi: 10.1007/s00394-012-0418-1. Epub 2012 Jul 19. Review.</citation>
    <PMID>22810464</PMID>
  </reference>
  <reference>
    <citation>Scharf RJ, Demmer RT, DeBoer MD. Longitudinal evaluation of milk type consumed and weight status in preschoolers. Arch Dis Child. 2013 May;98(5):335-40. doi: 10.1136/archdischild-2012-302941. Epub 2013 Mar 18.</citation>
    <PMID>23508869</PMID>
  </reference>
  <reference>
    <citation>Li, S., Field, A., Rimm, E. &amp; Flint, A. Dairy consumption with onset of overweight and obesity among U.S. adolescents. FASEB J 28, 370.7 (2014).</citation>
  </reference>
  <reference>
    <citation>Kratz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS, Song X, Di C, Utzschneider KM. Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. Am J Clin Nutr. 2014 Jun;99(6):1385-96. doi: 10.3945/ajcn.113.075457. Epub 2014 Apr 16.</citation>
    <PMID>24740208</PMID>
  </reference>
  <reference>
    <citation>Yakoob MY, Shi P, Willett WC, Rexrode KM, Campos H, Orav EJ, Hu FB, Mozaffarian D. Circulating Biomarkers of Dairy Fat and Risk of Incident Diabetes Mellitus Among Men and Women in the United States in Two Large Prospective Cohorts. Circulation. 2016 Apr 26;133(17):1645-54. doi: 10.1161/CIRCULATIONAHA.115.018410. Epub 2016 Mar 22.</citation>
    <PMID>27006479</PMID>
  </reference>
  <reference>
    <citation>Ericson U, Hellstrand S, Brunkwall L, Schulz CA, Sonestedt E, Wallström P, Gullberg B, Wirfält E, Orho-Melander M. Food sources of fat may clarify the inconsistent role of dietary fat intake for incidence of type 2 diabetes. Am J Clin Nutr. 2015 May;101(5):1065-80. doi: 10.3945/ajcn.114.103010. Epub 2015 Apr 1.</citation>
    <PMID>25832335</PMID>
  </reference>
  <reference>
    <citation>Gijsbers L, Ding EL, Malik VS, de Goede J, Geleijnse JM, Soedamah-Muthu SS. Consumption of dairy foods and diabetes incidence: a dose-response meta-analysis of observational studies. Am J Clin Nutr. 2016 Apr;103(4):1111-24. doi: 10.3945/ajcn.115.123216. Epub 2016 Feb 24. Review.</citation>
    <PMID>26912494</PMID>
  </reference>
  <reference>
    <citation>Jensen RG. The composition of bovine milk lipids: January 1995 to December 2000. J Dairy Sci. 2002 Feb;85(2):295-350. Review.</citation>
    <PMID>11913692</PMID>
  </reference>
  <reference>
    <citation>Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? Nutr Clin Pract. 2006 Aug;21(4):351-66. Review.</citation>
    <PMID>16870803</PMID>
  </reference>
  <reference>
    <citation>Barber MC, Clegg RA, Travers MT, Vernon RG. Lipid metabolism in the lactating mammary gland. Biochim Biophys Acta. 1997 Aug 16;1347(2-3):101-26. Review.</citation>
    <PMID>9295156</PMID>
  </reference>
  <reference>
    <citation>Keeney, M. K., Katz, I. &amp; Allison, M.J. On the probable origin of some milk fat acids in rumen microbial lipids. J Am Oil Chem Soc 39, 198-201 (1962).</citation>
  </reference>
  <reference>
    <citation>Jenkins B, West JA, Koulman A. A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. Molecules. 2015 Jan 30;20(2):2425-44. doi: 10.3390/molecules20022425. Review.</citation>
    <PMID>25647578</PMID>
  </reference>
  <reference>
    <citation>Palmquist DL, Lock AL, Shingfield KJ, Bauman DE. Biosynthesis of conjugated linoleic acid in ruminants and humans. Adv Food Nutr Res. 2005;50:179-217. Review.</citation>
    <PMID>16263431</PMID>
  </reference>
  <reference>
    <citation>Shingfield KJ, Chilliard Y, Toivonen V, Kairenius P, Givens DI. Trans fatty acids and bioactive lipids in ruminant milk. Adv Exp Med Biol. 2008;606:3-65. doi: 10.1007/978-0-387-74087-4_1. Review.</citation>
    <PMID>18183924</PMID>
  </reference>
  <reference>
    <citation>Bainbridge ML, Cersosimo LM, Wright AD, Kraft J. Content and Composition of Branched-Chain Fatty Acids in Bovine Milk Are Affected by Lactation Stage and Breed of Dairy Cow. PLoS One. 2016 Mar 1;11(3):e0150386. doi: 10.1371/journal.pone.0150386. eCollection 2016.</citation>
    <PMID>26930646</PMID>
  </reference>
  <reference>
    <citation>Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002 Aug;61(3):345-58. Review.</citation>
    <PMID>12296294</PMID>
  </reference>
  <reference>
    <citation>Antoniades C, Bakogiannis C, Tousoulis D, Demosthenous M, Marinou K, Stefanadis C. Platelet activation in atherogenesis associated with low-grade inflammation. Inflamm Allergy Drug Targets. 2010 Dec;9(5):334-45. Review.</citation>
    <PMID>20632958</PMID>
  </reference>
  <reference>
    <citation>Bohl M, Bjørnshave A, Gregersen S, Hermansen K. Whey and Casein Proteins and Medium-Chain Saturated Fatty Acids from Milk Do Not Increase Low-Grade Inflammation in Abdominally Obese Adults. Rev Diabet Stud. 2016 Summer-Fall;13(2-3):148-157. Epub 2016 Mar 14.</citation>
    <PMID>28012280</PMID>
  </reference>
  <reference>
    <citation>Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, Esposito K, Jönsson LS, Kolb H, Lansink M, Marcos A, Margioris A, Matusheski N, Nordmann H, O'Brien J, Pugliese G, Rizkalla S, Schalkwijk C, Tuomilehto J, Wärnberg J, Watzl B, Winklhofer-Roob BM. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011 Dec;106 Suppl 3:S5-78. doi: 10.1017/S0007114511005460. Review.</citation>
    <PMID>22133051</PMID>
  </reference>
  <reference>
    <citation>Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012 Jul-Aug;3(4):279-88. Epub 2012 May 14. Review.</citation>
    <PMID>22572877</PMID>
  </reference>
  <reference>
    <citation>Lallès JP. Dairy products and the French paradox: Could alkaline phosphatases play a role? Med Hypotheses. 2016 Jul;92:7-11. doi: 10.1016/j.mehy.2016.04.033. Epub 2016 Apr 20.</citation>
    <PMID>27241245</PMID>
  </reference>
  <reference>
    <citation>Misiak B, Leszek J, Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull. 2012 Nov 1;89(3-4):144-9. doi: 10.1016/j.brainresbull.2012.08.003. Epub 2012 Aug 18. Review.</citation>
    <PMID>22921944</PMID>
  </reference>
  <reference>
    <citation>Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010 Sep;120(3):277-86. doi: 10.1007/s00401-010-0722-x. Epub 2010 Jul 20. Review.</citation>
    <PMID>20644946</PMID>
  </reference>
  <reference>
    <citation>Vitale G, Salvioli S, Franceschi C. Oxidative stress and the ageing endocrine system. Nat Rev Endocrinol. 2013 Apr;9(4):228-40. doi: 10.1038/nrendo.2013.29. Epub 2013 Feb 26. Review.</citation>
    <PMID>23438835</PMID>
  </reference>
  <reference>
    <citation>Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998 Dec 4;273(49):32833-41.</citation>
    <PMID>9830030</PMID>
  </reference>
  <reference>
    <citation>Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes. 2010 Aug 30;3:285-95. doi: 10.2147/DMSOTT.S7384.</citation>
    <PMID>21437097</PMID>
  </reference>
  <reference>
    <citation>Ferdinand, K. C. et al. Health economics of cardiovascular disease: Defining the research agenda. CVD Prev Control 6, 91-100 (2011).</citation>
  </reference>
  <reference>
    <citation>O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015 Jan;16(1):1-12. doi: 10.1111/obr.12229. Epub 2014 Nov 18. Review.</citation>
    <PMID>25407540</PMID>
  </reference>
  <reference>
    <citation>Barbaresko J, Koch M, Schulze MB, Nöthlings U. Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review. Nutr Rev. 2013 Aug;71(8):511-27. doi: 10.1111/nure.12035. Epub 2013 Jun 13. Review.</citation>
    <PMID>23865797</PMID>
  </reference>
  <reference>
    <citation>Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, Teeling JL, Blaak EE, Fenech M, Vauzour D, McArdle HJ, Kremer BH, Sterkman L, Vafeiadou K, Benedetti MM, Williams CM, Calder PC. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 2015 Oct 14;114(7):999-1012. doi: 10.1017/S0007114515002093. Epub 2015 Jul 31. Review.</citation>
    <PMID>26228057</PMID>
  </reference>
  <reference>
    <citation>Panagiotakos DB, Pitsavos CH, Zampelas AD, Chrysohoou CA, Stefanadis CI. Dairy products consumption is associated with decreased levels of inflammatory markers related to cardiovascular disease in apparently healthy adults: the ATTICA study. J Am Coll Nutr. 2010 Aug;29(4):357-64.</citation>
    <PMID>21041810</PMID>
  </reference>
  <reference>
    <citation>Labonté MÈ, Couture P, Richard C, Desroches S, Lamarche B. Impact of dairy products on biomarkers of inflammation: a systematic review of randomized controlled nutritional intervention studies in overweight and obese adults. Am J Clin Nutr. 2013 Apr;97(4):706-17. doi: 10.3945/ajcn.112.052217. Epub 2013 Feb 27. Review.</citation>
    <PMID>23446894</PMID>
  </reference>
  <reference>
    <citation>Bordoni A, Danesi F, Dardevet D, Dupont D, Fernandez AS, Gille D, Nunes Dos Santos C, Pinto P, Re R, Rémond D, Shahar DR, Vergères G. Dairy products and inflammation: A review of the clinical evidence. Crit Rev Food Sci Nutr. 2017 Aug 13;57(12):2497-2525. doi: 10.1080/10408398.2014.967385. Review.</citation>
    <PMID>26287637</PMID>
  </reference>
  <reference>
    <citation>Calder PC. Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol. 2011 Sep;668 Suppl 1:S50-8. doi: 10.1016/j.ejphar.2011.05.085. Epub 2011 Jul 28. Review.</citation>
    <PMID>21816146</PMID>
  </reference>
  <reference>
    <citation>Kien CL, Bunn JY, Fukagawa NK, Anathy V, Matthews DE, Crain KI, Ebenstein DB, Tarleton EK, Pratley RE, Poynter ME. Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. J Nutr Biochem. 2015 Dec;26(12):1599-606. doi: 10.1016/j.jnutbio.2015.07.014. Epub 2015 Aug 1.</citation>
    <PMID>26324406</PMID>
  </reference>
  <reference>
    <citation>Kien CL, Bunn JY, Poynter ME, Stevens R, Bain J, Ikayeva O, Fukagawa NK, Champagne CM, Crain KI, Koves TR, Muoio DM. A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. Diabetes. 2013 Apr;62(4):1054-63. doi: 10.2337/db12-0363. Epub 2012 Dec 13.</citation>
    <PMID>23238293</PMID>
  </reference>
  <reference>
    <citation>Kien CL, Matthews DE, Poynter ME, Bunn JY, Fukagawa NK, Crain KI, Ebenstein DB, Tarleton EK, Stevens RD, Koves TR, Muoio DM. Increased palmitate intake: higher acylcarnitine concentrations without impaired progression of β-oxidation. J Lipid Res. 2015 Sep;56(9):1795-807. doi: 10.1194/jlr.M060137. Epub 2015 Jul 8.</citation>
    <PMID>26156077</PMID>
  </reference>
  <reference>
    <citation>Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011 Oct;3(10):858-76. doi: 10.3390/nu3100858. Epub 2011 Oct 14. Review.</citation>
    <PMID>22254083</PMID>
  </reference>
  <reference>
    <citation>Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9. Review.</citation>
    <PMID>24388214</PMID>
  </reference>
  <reference>
    <citation>Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, Bamba T. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol. 1999 Oct;118(1):23-9.</citation>
    <PMID>10540155</PMID>
  </reference>
  <reference>
    <citation>Sales-Campos H, Souza PR, Peghini BC, da Silva JS, Cardoso CR. An overview of the modulatory effects of oleic acid in health and disease. Mini Rev Med Chem. 2013 Feb;13(2):201-10. Review.</citation>
    <PMID>23278117</PMID>
  </reference>
  <reference>
    <citation>Vassiliou EK, Gonzalez A, Garcia C, Tadros JH, Chakraborty G, Toney JH. Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems. Lipids Health Dis. 2009 Jun 26;8:25. doi: 10.1186/1476-511X-8-25.</citation>
    <PMID>19558671</PMID>
  </reference>
  <reference>
    <citation>Carrillo C, Cavia Mdel M, Alonso-Torre S. Role of oleic acid in immune system; mechanism of action; a review. Nutr Hosp. 2012 Jul-Aug;27(4):978-90. doi: 10.3305/nh.2012.27.4.5783. Review.</citation>
    <PMID>23165533</PMID>
  </reference>
  <reference>
    <citation>Jacome-Sosa M, Vacca C, Mangat R, Diane A, Nelson RC, Reaney MJ, Shen J, Curtis JM, Vine DF, Field CJ, Igarashi M, Piomelli D, Banni S, Proctor SD. Vaccenic acid suppresses intestinal inflammation by increasing anandamide and related N-acylethanolamines in the JCR:LA-cp rat. J Lipid Res. 2016 Apr;57(4):638-49. doi: 10.1194/jlr.M066308. Epub 2016 Feb 17.</citation>
    <PMID>26891736</PMID>
  </reference>
  <reference>
    <citation>Jaudszus A, Jahreis G, Schlörmann W, Fischer J, Kramer R, Degen C, Rohrer C, Roth A, Gabriel H, Barz D, Gruen M. Vaccenic acid-mediated reduction in cytokine production is independent of c9,t11-CLA in human peripheral blood mononuclear cells. Biochim Biophys Acta. 2012 Oct;1821(10):1316-22. doi: 10.1016/j.bbalip.2012.06.010. Epub 2012 Jun 30.</citation>
    <PMID>22750019</PMID>
  </reference>
  <reference>
    <citation>Huebner SM, Olson JM, Campbell JP, Bishop JW, Crump PM, Cook ME. Low Dietary c9t11-Conjugated Linoleic Acid Intake from Dairy Fat or Supplements Reduces Inflammation in Collagen-Induced Arthritis. Lipids. 2016 Jul;51(7):807-19. doi: 10.1007/s11745-016-4163-8. Epub 2016 Jun 7.</citation>
    <PMID>27270404</PMID>
  </reference>
  <reference>
    <citation>Penedo LA, Nunes JC, Gama MA, Leite PE, Quirico-Santos TF, Torres AG. Intake of butter naturally enriched with cis9,trans11 conjugated linoleic acid reduces systemic inflammatory mediators in healthy young adults. J Nutr Biochem. 2013 Dec;24(12):2144-51. doi: 10.1016/j.jnutbio.2013.08.006.</citation>
    <PMID>24231103</PMID>
  </reference>
  <reference>
    <citation>Reynolds CM, Roche HM. Conjugated linoleic acid and inflammatory cell signalling. Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):199-204. doi: 10.1016/j.plefa.2010.02.021. Epub 2010 Mar 7. Review.</citation>
    <PMID>20207526</PMID>
  </reference>
  <reference>
    <citation>Stachowska E, Siennicka A, Baśkiewcz-Hałasa M, Bober J, Machalinski B, Chlubek D. Conjugated linoleic acid isomers may diminish human macrophages adhesion to endothelial surface. Int J Food Sci Nutr. 2012 Feb;63(1):30-5. doi: 10.3109/09637486.2011.593505. Epub 2011 Jul 1.</citation>
    <PMID>21721848</PMID>
  </reference>
  <reference>
    <citation>Viladomiu M, Hontecillas R, Bassaganya-Riera J. Modulation of inflammation and immunity by dietary conjugated linoleic acid. Eur J Pharmacol. 2016 Aug 15;785:87-95. doi: 10.1016/j.ejphar.2015.03.095. Epub 2015 May 15. Review.</citation>
    <PMID>25987426</PMID>
  </reference>
  <reference>
    <citation>Poudel-Tandukar K, Nanri A, Matsushita Y, Sasaki S, Ohta M, Sato M, Mizoue T. Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men. Nutr Res. 2009 Jun;29(6):363-70. doi: 10.1016/j.nutres.2009.05.012.</citation>
    <PMID>19628101</PMID>
  </reference>
  <reference>
    <citation>Reifen R, Karlinsky A, Stark AH, Berkovich Z, Nyska A. α-Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease. J Nutr Biochem. 2015 Dec;26(12):1632-40. doi: 10.1016/j.jnutbio.2015.08.006. Epub 2015 Aug 14.</citation>
    <PMID>26350254</PMID>
  </reference>
  <reference>
    <citation>Ren J, Chung SH. Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways. J Agric Food Chem. 2007 Jun 27;55(13):5073-80. Epub 2007 Jun 2.</citation>
    <PMID>17542608</PMID>
  </reference>
  <reference>
    <citation>Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr. 2007 Feb;85(2):385-91.</citation>
    <PMID>17284733</PMID>
  </reference>
  <reference>
    <citation>Mika A, Stepnowski P, Kaska L, Proczko M, Wisniewski P, Sledzinski M, Sledzinski T. A comprehensive study of serum odd- and branched-chain fatty acids in patients with excess weight. Obesity (Silver Spring). 2016 Aug;24(8):1669-76. doi: 10.1002/oby.21560. Epub 2016 Jun 29.</citation>
    <PMID>27355152</PMID>
  </reference>
  <reference>
    <citation>Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Avershina E, Rudi K, Narbad A, Jenmalm MC, Marchesi JR, Collado MC. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015 Feb 2;26:26050. doi: 10.3402/mehd.v26.26050. eCollection 2015.</citation>
    <PMID>25651996</PMID>
  </reference>
  <reference>
    <citation>Salminen S, Gibson GR, McCartney AL, Isolauri E. Influence of mode of delivery on gut microbiota composition in seven year old children. Gut. 2004 Sep;53(9):1388-9.</citation>
    <PMID>15306608</PMID>
  </reference>
  <reference>
    <citation>Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014 Apr 29;5:190. doi: 10.3389/fmicb.2014.00190. eCollection 2014. Review.</citation>
    <PMID>24808896</PMID>
  </reference>
  <reference>
    <citation>Mai V, Draganov PV. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol. 2009 Jan 7;15(1):81-5. Review.</citation>
    <PMID>19115471</PMID>
  </reference>
  <reference>
    <citation>Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220-30. doi: 10.1038/nature11550. Review.</citation>
    <PMID>22972295</PMID>
  </reference>
  <reference>
    <citation>Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13;486(7402):207-14. doi: 10.1038/nature11234.</citation>
    <PMID>22699609</PMID>
  </reference>
  <reference>
    <citation>Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014 Nov 21;20(43):16079-94. doi: 10.3748/wjg.v20.i43.16079. Review.</citation>
    <PMID>25473159</PMID>
  </reference>
  <reference>
    <citation>Graf D, Di Cagno R, Fåk F, Flint HJ, Nyman M, Saarela M, Watzl B. Contribution of diet to the composition of the human gut microbiota. Microb Ecol Health Dis. 2015 Feb 4;26:26164. doi: 10.3402/mehd.v26.26164. eCollection 2015.</citation>
    <PMID>25656825</PMID>
  </reference>
  <reference>
    <citation>Zimmer J, Lange B, Frick JS, Sauer H, Zimmermann K, Schwiertz A, Rusch K, Klosterhalfen S, Enck P. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr. 2012 Jan;66(1):53-60. doi: 10.1038/ejcn.2011.141. Epub 2011 Aug 3.</citation>
    <PMID>21811294</PMID>
  </reference>
  <reference>
    <citation>David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11.</citation>
    <PMID>24336217</PMID>
  </reference>
  <reference>
    <citation>Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. Cell Metab. 2015 Oct 6;22(4):658-68. doi: 10.1016/j.cmet.2015.07.026. Epub 2015 Aug 27.</citation>
    <PMID>26321659</PMID>
  </reference>
  <reference>
    <citation>Caesar R, Nygren H, Orešič M, Bäckhed F. Interaction between dietary lipids and gut microbiota regulates hepatic cholesterol metabolism. J Lipid Res. 2016 Mar;57(3):474-81. doi: 10.1194/jlr.M065847. Epub 2016 Jan 18.</citation>
    <PMID>26783361</PMID>
  </reference>
  <reference>
    <citation>Walsh, H. H., H.; Cersosimo, L.; Kien, C.L.; Kraft, J. Decreased abundance of firmicutes in the gut microbiota after consumption of a diet containing milk fats. FASEB J 30, 683.611 (2016).</citation>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont Medical Center</investigator_affiliation>
    <investigator_full_name>Jana Kraft</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Glucose Tolerance</keyword>
  <keyword>Bioactive fatty acids</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Diet</keyword>
  <keyword>Milk fat</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Inflammation markers</keyword>
  <keyword>Fecal microbiota composition</keyword>
  <keyword>Dairy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

